Last reviewed · How we verify
CimetrA-1
CimetrA-1 is a cannabinoid-based therapeutic that modulates endocannabinoid system signaling to produce anti-inflammatory and neuroprotective effects.
CimetrA-1 is a cannabinoid-based therapeutic that modulates endocannabinoid system signaling to produce anti-inflammatory and neuroprotective effects. Used for Neurological or inflammatory conditions (specific indication not publicly disclosed).
At a glance
| Generic name | CimetrA-1 |
|---|---|
| Also known as | CimetrA-1 drug administration |
| Sponsor | MGC Pharmaceuticals d.o.o |
| Drug class | Cannabinoid therapeutic |
| Modality | Small molecule |
| Therapeutic area | Neurology / Immunology |
| Phase | Phase 3 |
Mechanism of action
CimetrA-1 is developed by MGC Pharmaceuticals as a cannabis-derived or cannabinoid pharmaceutical candidate. It is designed to interact with cannabinoid receptors and the endocannabinoid system to reduce inflammation and provide therapeutic benefit in neurological or inflammatory conditions. The exact molecular mechanism and primary target remain proprietary, but the drug is positioned within the emerging cannabinoid therapeutics space.
Approved indications
- Neurological or inflammatory conditions (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (PHASE2)
- Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CimetrA-1 CI brief — competitive landscape report
- CimetrA-1 updates RSS · CI watch RSS
- MGC Pharmaceuticals d.o.o portfolio CI